A fluorescent immunoassay myocardial multiplex kit and preparation method thereof
By using fluorescent microsphere-antibody conjugates and biotin-streptavidin labeling technology, combined with nitrocellulose membranes, a rapid and accurate detection of multiple cardiovascular indicators in a fluorescent immunoassay kit for myocardial multiplex detection was achieved, solving the problem of long detection times for single items in existing technologies.
Patent Information
- Application Number
- CN202210255003.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-03-15
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-03-15
AI Technical Summary
Existing fluorescent immunoassay kits for myocardial infarction can only detect one indicator at a time. Multiple indicators need to be tested in batches, which is time-consuming.
This invention provides a fluorescent immunoassay kit for myocardial multiplex detection, which uses fluorescent microsphere-antibody conjugate and biotin-streptavidin labeling technology, combined with nitrocellulose membrane, to achieve simultaneous detection of multiple cardiovascular indicators.
It enables rapid and accurate detection of multiple cardiovascular indicators, and quantitative results can be obtained within 15 minutes, improving detection efficiency and sensitivity.
Smart Images

Figure CN114563581B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biological monitoring technology, and in particular to a fluorescent immunoassay myocardial multiplex kit and a preparation method thereof. Background Art
[0002] Troponin l (cTnl), myoglobin (MYO) and creatine kinase isoenzyme (CK-MB) are all related to myocardial cell damage. High-sensitivity C-reactive protein (hsCRP) is a non-specific marker of the acute phase of systemic inflammatory response synthesized by the liver and is one of the most powerful predictors of cardiovascular events. B-type natriuretic peptide (BNP) is an amino acid substance secreted by myocardial cells in the atria and ventricles when stimulated. It is one of the most common biomarkers of heart failure in clinical work. D-dimer is the simplest fibrin degradation product. Elevated D-dimer levels indicate the presence of a hypercoagulable state and secondary hyperfibrinolysis in the body. Therefore, the combined detection of these indicators is of great significance for the diagnosis, efficacy evaluation and prognosis of cardiovascular diseases.
[0003] Currently, some fluorescent immunoassay myocardial detection kits on the market mostly carry separate test cards, which can only detect one indicator at a time. Multiple indicators need to be tested in batches, which consumes a lot of manpower and takes a long time. Summary of the invention
[0004] The purpose of the present application is to provide a fluorescent immunoassay myocardial multiplex kit, which can rapidly and accurately detect troponin l (cTnl) / myoglobin (MYO) / creatine kinase isoenzyme (CK-MB) / high-sensitivity C-reactive protein (hsCRP) / B-type natriuretic peptide (BNP) / D-dimer (D-Dimer) to meet the needs of qualitative and quantitative analysis. The kit can be used with instruments to detect multiple items at the same time.
[0005] Another object of the present application is to provide a method for preparing a fluorescent immunoassay multiple myocardial cell test kit, which has a simple process, low cost, and accurate and reliable test results.
[0006] The present application solves the technical problem by adopting the following technical solution.
[0007] On the one hand, the embodiment of the present application provides a fluorescent immunoassay myocardial multiplex kit, comprising: a housing, a chromatography buffer, and a plurality of detection cards disposed on the housing;
[0008] At least three card slots are arranged in the housing, and the detection cards correspond to the card slots one by one;
[0009] The above-mentioned detection card comprises a bottom plate and a blood filter pad, a gold spray pad, a detection pad and a water absorbent pad overlapped on the above-mentioned bottom plate;
[0010] The gold-sprayed pad is sprayed with fluorescent microsphere-antibody conjugates, and the detection pad is provided with a detection band and a quality control band. The detection band is coated with a preset antibody; the quality control band is coated with biotinylated-BSA.
[0011] The above antibodies are at least three of: troponin I antibody, myoglobin antibody, creatine kinase isoenzyme antibody, hypersensitivity, C-reactive protein antibody, B-type natriuretic peptide antibody, and D-dimer antibody.
[0012] On the other hand, the present application provides a method for preparing a fluorescent immunoassay myocardial multiplex kit, and the preparation steps are as follows:
[0013] Activating the fluorescent microspheres, coupling the preset antibodies on the surface of the microspheres after activation, modifying them with streptavidin to obtain fluorescent microsphere-antibody conjugates, spraying the fluorescent microsphere-antibody conjugates on the glass fiber membrane, and drying them for later use;
[0014] Use nitrocellulose membrane as the detection pad chromatography test paper, coat the front end of the membrane strip with detection antibody as the detection band T line, and coat the back end of the membrane strip with biotinylated-BSA as the quality control band C line. After the antibody coating is drawn, it is dried and baked for use;
[0015] The blood filter pad, the gold spray pad, the detection pad and the water absorbent pad are sequentially bonded to the bottom plate and laminated tightly, and then the laminated film strips are cut to obtain the detection card, and then the detection card is matched to the card slot on the above-mentioned shell;
[0016] Finally, the prepared chromatography buffer and the assembled detection card are packed into a box to obtain a test kit.
[0017] Compared with the prior art, the embodiments of the present application have at least the following advantages or beneficial effects:
[0018] 1. This application is based on fluorescent immunochromatography and combined with biotin-streptavidin labeling technology to provide a high-sensitivity antigen detection card and its preparation method. The biotin-streptavidin system has the characteristics of high specificity, high sensitivity and high stability, which further improves the specificity and sensitivity of various tracer immunoassays.
[0019] 2. The fluorescent immunoassay myocardial multi-test kit provided in this application can detect six cardiovascular indicators at one time, with a short detection time. The test results can be obtained within 15 minutes, and the quantitative concentration of each indicator can be obtained, providing data support for the clinical diagnosis of cardiovascular diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.
[0021] Figure 1 This is a sample loading surface of a fluorescent immunoassay myocardial multiplex kit according to an embodiment of the present application;
[0022] Figure 2 This is the result observation surface of a fluorescent immunoassay myocardial multiplex kit according to an embodiment of the present application;
[0023] Figure 3 This is a schematic diagram of the structure of the detection card in the myocardial multiplex kit for fluorescent immunoassay detection according to the embodiment of the present application;
[0024] Icon: 100-housing, 110-sample adding area, 120-mixing tank, 140-QR code, 200-test card, 201-blood filter pad, 202-gold spray pad, 203-test pad, 204-absorbent pad, 205-test tape, 206-quality control tape, 207-bottom plate, 210-marking area. DETAILED DESCRIPTION
[0025] In order to make the purpose, technical scheme and advantages of the embodiments of the present application clearer, the technical scheme in the embodiments of the present application will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.
[0026] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present application will be described in detail below with reference to specific embodiments.
[0027] The present application provides a fluorescent immunoassay myocardial multiplex kit, comprising: a housing, a chromatography buffer, and a plurality of detection cards arranged on the housing;
[0028] At least three card slots are arranged in the housing, and the detection cards correspond to the card slots one by one;
[0029] The above-mentioned detection card comprises a bottom plate and a blood filter pad, a gold spray pad, a detection pad and a water absorbent pad overlapped on the above-mentioned bottom plate;
[0030] The gold-sprayed pad is sprayed with a fluorescent microsphere-antibody conjugate, and the detection pad is provided with a detection band and a quality control band, wherein the detection band is coated with a preset antibody; and the quality control band is coated with biotinylated-BSA;
[0031] The above antibodies are at least three of: troponin I antibody, myoglobin antibody, creatine kinase isoenzyme antibody, hypersensitivity, C-reactive protein antibody, B-type natriuretic peptide antibody, and D-dimer antibody.
[0032] It should be noted that, in some embodiments of the present application, when achieving the above detection purpose, the fluorescent microsphere coupling complex and the substance coated on the quality control strip can be equivalently replaced in the following manner:
[0033] Ⅰ. The antibody of the fluorescent microsphere-coupled complex is a mammalian antibody, such as mouse antibody, and the quality control strip is coated with the corresponding secondary antibody, such as rabbit anti-mouse IgG;
[0034] Ⅱ. The antibody of the fluorescent microsphere-coupled complex is a non-mammalian antibody, such as IgY, and the quality control strip is coated with the corresponding secondary antibody, such as anti-IgY antibody;
[0035] III. The fluorescent microsphere coupling complex uses DNP (Dinitrophenyl, 1,3-dinitrobenzene) and antibody coupled microspheres, and the quality control strip is coated with BSA-DNP.
[0036] The multi-test kit of the present application can detect multiple cardiovascular-related indicators at one time, with short time consumption, simple operation and convenient carrying.
[0037] In an embodiment of the present application, a sample adding area is provided on the housing, and the sample adding area is connected to the blood filter pad for convenient sample adding.
[0038] In an embodiment of the present application, a mixing tank is provided on the housing to facilitate placing samples and chromatography buffer therein for dilution.
[0039] In the embodiment of the present application, the fluorescent microsphere-antibody conjugate contains streptavidin. Avidin and enzyme-labeled biotin can form an avidin-biotin-peroxidase complex, which, when in contact with the biotinylated antibody, can amplify the signal of trace antigens by thousands of times for easy detection.
[0040] In the embodiments of the present application, the chromatography buffer comprises the following components: 0.1-0.2 mM phosphate buffer, 0.1-0.5% by volume of Tween-20, and 0.1-0.2% by volume of Proclin 300 preservative.
[0041] The present application also provides a method for preparing a fluorescent immunoassay myocardial multiplex kit, the preparation steps of which are as follows:
[0042] Activating the fluorescent microspheres, coupling the preset antibodies on the surface of the microspheres after activation, modifying them with streptavidin to obtain fluorescent microsphere-antibody conjugates, spraying the fluorescent microsphere-antibody conjugates on the glass fiber membrane, and drying them for later use;
[0043] Use nitrocellulose membrane as the detection pad chromatography test paper, coat the front end of the membrane strip with detection antibody as the detection band T line, and coat the back end of the membrane strip with biotinylated-BSA as the quality control band C line. After the antibody coating is drawn, it is dried and baked for use;
[0044] The blood filter pad, the gold spray pad, the detection pad and the water absorbent pad are sequentially bonded to the bottom plate and laminated tightly, and then the laminated film strips are cut to obtain the detection card, and then the detection card is matched to the card slot on the above-mentioned shell;
[0045] Finally, the prepared chromatography buffer and the assembled detection card are packed into a box to obtain a test kit.
[0046] In the embodiments of the present application, the storage solution of the fluorescent microsphere-antibody conjugate comprises: a phosphate buffer solution with a concentration of 0.1 to 1 mM, a Tween-20 with a volume percentage of 0.01 to 4%, a preservative with a volume percentage of 0.05 to 0.1%, and a protein with a mass percentage of 0.1 to 0.5%.
[0047] In the examples of the present application, the spraying concentration of the fluorescent microsphere-antibody conjugate is 1.0-1.2 mg / mL, which is set according to the commonly used standards of this production workshop.
[0048] In the embodiment of the present application, the drying of the detection pad is specifically air-drying at 20-30°C for 1 hour, and the baking step is specifically baking at 37°C for 12 hours, and then baking at 60°C for 72 hours. The detection pad is fully dried to reduce the probability of microbial survival and extend the shelf life.
[0049] As a general inventive concept, the present application also provides an application of a fluorescent immunoassay myocardial multi-test kit in the detection of cardiovascular index concentrations. The method is simple to operate, short in time, and can obtain quantitative concentrations of multiple detection indicators at one time, which can provide support for doctors' clinical diagnosis.
[0050] The features and performance of the present application are further described in detail below in conjunction with the embodiments.
[0051] Example 1
[0052] This embodiment provides a myocardial fluorescence immunoassay multiplex kit and a preparation method thereof.
[0053] like Figure 1As shown, a detection reagent card in a fluorescent immunoassay myocardial multiplex kit provided in this embodiment includes: a housing 100 and 6 detection cards 200 for detecting different indicators, and the 6 detection cards 200 are separately arranged in the card slots of the housing 100; Figure 3 As shown, the detection card includes a blood filter pad 201, a gold-sprayed pad 202, a detection pad 203 and a water-absorbing pad 204 which are sequentially overlapped on a bottom plate 207; the gold-sprayed pad 202 is sprayed with a fluorescent microsphere-antibody conjugate, and the fluorescent microsphere-antibody conjugate includes fluorescent microspheres, and streptavidin and a preset antibody coupled to the fluorescent microspheres; the detection pad 203 is provided with a detection belt 205 and a quality control belt 206, the detection belt 205 is coated with an antibody of a to-be-tested indicator, and the quality control belt 206 is fixed with biotinylated-BSA.
[0054] Refer to Figure 1 A sample adding area 110 is also provided at the blood filter pad 201. The blood filter pad 201 is connected with the sample adding area 110 for convenient sample adding.
[0055] In this embodiment, the housing 100 is provided with two mixing grooves 120 for mixing samples. The samples and the chromatography buffer solution can be mixed by adding them into the mixing grooves 120. The housing 100 is provided with a marking area 210 for marking different detection indicators. Different antibodies or antigens are used for different indicators. In order to avoid confusion and errors, color markings or text markings are set on the housing 100 to facilitate the experimenter to identify and add samples.
[0056] like Figure 2 As shown, in this embodiment, a QR code 140 is also provided on the housing. By scanning the QR code, standard curve information of various indicators can be obtained, and the concentration of each indicator can be calculated according to the standard curve to achieve quantitative detection. It should be noted that in order to reduce intra-batch differences, the standard curves of different batches of multi-link test kits are different, and each batch of multi-link test kits needs to prepare standard curves of six indicators.
[0057] The working principle of the kit is as follows: a certain amount of sample is taken and diluted with chromatography buffer, and the diluted chromatography solution is titrated to the sample adding area 110. The mixed blood cells in the diluted chromatography solution will be filtered on the blood filter pad 201. The serum dilution solution flows along the fiber gaps by capillary action, first passes through the gold-sprayed pad 202 to mix with the microspheres, and flows along the gaps of the detection pad 203 with the microspheres, successively flows through the detection belt 205T line and the quality control belt 206C line, and is finally absorbed by the absorbent pad 204. During the entire flow process of the serum diluent, the serum diluent first contacts the microspheres and then produces the first immune reaction, and the antigen to be detected in the serum will bind to the detection antibody A on the microspheres; when the serum diluent mixed with the microspheres flows through the detection belt 205T line, the antigen bound to the microspheres binds to the detection antibody B on the detection belt 205, so that the microspheres bound to the antigens will be fixed on the detection belt 205T line; as the serum diluent mixed with the microspheres continues to flow through the quality control belt 206C line, the microspheres that are not bound to the antigens produce a third immune reaction through streptavidin and the biotinylated-BSA on the quality control belt 206C line, and the microspheres are bound to the quality control belt C line.
[0058] This embodiment detects 6 myocardial indices, namely: troponin l (cTnl), myoglobin (MYO), creatine kinase isoenzyme (CK-MB), high-sensitivity C-reactive protein (hsCRP), B-type natriuretic peptide (BNP) and D-dimer (D-Dimer).
[0059] In addition, this embodiment also provides a method for preparing a fluorescent immunoassay myocardial multiplex kit, comprising the following steps:
[0060] 1. Preparation of blood filter pad:
[0061] Preparation of blood filter pad treatment solution (100 ml): 0.6 g tris (hydroxymethylaminomethane) (Tris-base), 0.1 g disodium ethylenediaminetetraacetic acid dihydrate (EDTA Na2·2H2O), 1 g bovine serum albumin (BSA), 0.5 g casein, 5 g trehalose, 2.5 ml 0.01 M PBS buffer, and 0.8 ml Tween-20.
[0062] Add appropriate amount of purified water to dissolve, make up to 100ml, adjust pH to 8.5 with dilute hydrochloric acid or sodium hydroxide, and mix well. Place a blood filter membrane on a clean tray, pour in the blood filter pad treatment solution, immerse the blood filter membrane, shake and soak on a horizontal shaker for 30 minutes, take out the blood filter membrane, place the treated blood filter membrane in a 37-degree biochemical incubator to dry for 24 hours, and recycle the blood filter membrane after drying for later use.
[0063] 2. Preparation of gold spray pad:
[0064] (1) Required reagents:
[0065] ① Polystyrene fluorescent microspheres: 1.05g / cm 3 , solid content 0.5%, diameter 160nm; ②50mM EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) 10ml; ③25mM sulfo-NHS (N-hydroxysuccinimide), 10ml; ④0.1M MES buffer, pH 5.0; ⑤10mM hydroxylamine hydrochloride pH=7.4; ⑥1×PBS 10mM, pH=7.4; ⑦Blocking solution: 1×PBS, 0.05% Tween-20, 1% BSA; ⑧Chromatography buffer: 1×PBS, 0.1% Tween-20, 2mMEDTA, pH=7.4, Proclin300, 0.1%; ⑨Microsphere preservation solution: 1×PBS, 0.02% Tween-20, 0.05% NaN3, 0.1% BSA; ⑩Antibody diluent: 1×PBS;
[0066] (2) Required equipment:
[0067] Centrifuge; inverted shaker; strip cutter; film dispenser; pH meter;
[0068] (3) Preparation process:
[0069] Red fluorescent microspheres were used as fluorescent markers. EDC and NHS were used to activate the surface carboxyl groups of the fluorescent microspheres. After activation, detection antibodies were coupled to the fluorescent microspheres. The antibody-coupled microspheres were sprayed on a glass fiber membrane (gold-sprayed pad) and dried for later use.
[0070] Preparation of gold-sprayed pad treatment solution (100 ml): weigh 1 g BSA, 6 g sucrose, and 1 g PVP-K30, add them into ultrapure water to dissolve, then measure 1 ml Tween 20 and add it into the mixture, stir evenly, and make up to 100 ml; place the glass fiber membrane in a clean tray, pour in the treatment solution, and soak it in a horizontal shaker for 30 minutes; place the treated gold-sprayed pad in a 37°C biochemical incubator to dry for 24 hours, and recover it for later use.
[0071] The obtained fluorescent microsphere-antibody conjugate was sprayed on the treated gold-sprayed pad using the gold-spraying function of the three-dimensional plane dot film spraying instrument, and the parameters were set; the gold-sprayed pad sprayed with the fluorescent microsphere-antibody conjugate was placed in a biochemical incubator at 37°C and baked for 24 hours. The baked gold-sprayed pad was placed in an aluminum foil bag, added with a desiccant, and placed in a 4°C refrigerator for later use.
[0072] The detailed steps for preparing the fluorescent microsphere-antibody conjugate are as follows:
[0073] First, aspirate 500 μL fluorescent microspheres into a 2 ml centrifuge tube, 12000 rpm × 20 min; discard the supernatant, add 500 μL 0.1 M MES, use a 200 μL pipette tip to suspend the nanoparticles, and ultrasonically oscillate for 1 min; 12000 rpm × 20 min; repeat step 2; then discard the supernatant, add 400 μL 0.1 M MES to the precipitate, resuspend the nanoparticles, and ultrasonically oscillate for 1 min; add 100 μL LEDC and NHS solution respectively, and incubate at room temperature for 1 h using a shaker (high speed); 12000 rpm × 20 min, discard the supernatant, add 500 μL 1× PBS to the precipitate to resuspend, ultrasonically oscillate at low temperature for 1 min, 12000 rpm × 5 min; discard the supernatant, add 500 μL 1× PBS to the precipitate to resuspend, ultrasonically oscillate at low temperature for 1 min, 12000 rpm × 5 min; discard the supernatant, add 500 μL The nanoparticles were resuspended in 1×PBS, ultrasonically vibrated for 1 min, the corresponding amount of streptavidin-modified antibodies were added, and PEG8000 with a mass fraction of 0.4% was added, and the mixture was incubated on a shaker for 8 h; the amount of antibody added was shown in Table 1; 12000 rpm×20 min, the supernatant was discarded, 500 μL 10 mM hydroxylamine hydrochloride was added to the precipitate, and the mixture was incubated on a shaker for 1 h; 12000 rpm×20 min, the supernatant was discarded, and the mixture was stored at 4°C; 125 μL of blocking solution was added to resuspend the nanoparticles, and the mixture was incubated on a shaker for 1 h; 12000 rpm×20 min, the supernatant was discarded, 125 μL of preservation solution was added to the precipitate to resuspend it, and the mixture was stored at 4°C.
[0074] Table 1 Antibody content required for the preparation of fluorescent microsphere-antibody conjugates
[0075]
[0076] 3. Preparation of test pad:
[0077] The immunochromatographic test strip using nitrocellulose membrane as the detection pad uses the membrane function of the three-dimensional plane dot membrane spraying instrument to coat the detection antibody at the front end of the membrane strip as the detection band T line, and the biotinylated-BSA at the back end of the membrane strip as the quality control band C line. Spray the T line about 1.2 cm away from the test card at one end, and spray the C line about 0.7 cm after the T line. The spraying volume and mass are designed according to Table 2, and dried for 1 hour; the coated nitrocellulose membrane strip is baked at 37 ° C overnight. Subsequently, the dried test pad is put away, packed in an aluminum foil bag, added with desiccant, sealed, and then placed in a 60 ° C biochemical incubator for 72 hours; take out the baked test pad and put it in a 4 ° C refrigerator for use.
[0078] Table 2 Antibody and biotinylated-BSA streaking amount on the test strip and quality control strip
[0079]
[0080] 4. Preparation of chromatography buffer (100 ml):
[0081] Add 0.1 ml Tween-20, 0.1 ml Proclin 300, and 2 mM EDTA to a glass container, then add 1× PBS solution and stir to dissolve, and adjust the pH to 7.4 with dilute hydrochloric acid or sodium hydroxide.
[0082] 5. Assembly:
[0083] The blood filter pad 201, the gold spray pad 202, the detection pad 203, and the water absorbent pad 204 are sequentially pasted on the bottom plate 207 and laminated tightly.
[0084] After lamination, the membrane strips are cut into suitable small sections according to specifications, where the test card is 2.5cm×0.5cm, the absorbent pad is 2cm×0.5cm, and the sample pad (blood pad) is 1.2cm×0.5cm. They are installed in the card slot of the shell to make a test reagent card.
[0085] Finally, the chromatography buffer and the detection reagent card are packaged into a box.
[0086] 6. Preparation of standard curve:
[0087] The kit was tested: Chromatographic parameters: serum / plasma 50 μL, whole blood 75 μL, buffer 150 μL, sample volume 75 μL, chromatography time 15 min.
[0088] Mix the sample to be tested and the chromatography buffer in the mixing tank, then add it to the sample adding area and react for a period of time before starting chromatography. Start timing, scan and read the results after the time is up.
[0089] The fluorescence intensity of the detection band T line and the quality control band C line is measured by optical equipment, which reflects the amount of microspheres bound to antigen and the amount of microspheres not bound to antigen, respectively.
[0090] Chromatography is performed using samples with known antigen concentrations, and the contrast values of the fluorescence intensities of the detection band T line and the quality control band C line at different concentrations are measured to create a standard curve formula.
[0091] When the finished test card is in use, the sample concentration can be calculated by measuring the contrast value of the fluorescence intensity of the test band T line and the quality control band C line on the test card after chromatography of the sample of unknown concentration, and then substituting it into the standard curve formula.
[0092] Result evaluation criteria: Prioritize the correlation between concentration and ratio, with R 2 As the evaluation criteria, R 2 The bigger the better.
[0093] Example 2
[0094] This embodiment is basically the same as embodiment 1, except that the formulas of the blocking solution, the preservation solution, the gold-spraying pad treatment solution, and the chromatography buffer solution are changed:
[0095] Table 3 Blocking solution formula
[0096]
[0097] Table 4 Preservative solution formula
[0098]
[0099] Table 5: Formulation of gold spray pad treatment solution
[0100]
[0101] Table 6 Formulation of chromatography buffer
[0102]
[0103] Example 3
[0104] This example is basically the same as Example 1, except that the antibody content in the preparation of the fluorescent microsphere-antibody conjugate and the change in the amount of lines drawn on the T line and C line of the detection pad are both 1.1 mg / mL.
[0105] Example 4
[0106] This example is basically the same as Example 1, except that the antibody content in the preparation of the fluorescent microsphere-antibody conjugate and the change in the amount of lines drawn on the T line and C line of the detection pad are both 1.2 mg / mL.
[0107] In summary, the fluorescent immunoassay myocardial multiplex kit of the embodiment of the present application has the characteristics of being able to simultaneously obtain multiple index test results, high efficiency and low cost. In addition, the preparation method of the fluorescent immunoassay myocardial multiplex kit of the embodiment of the present application is simple in process and low in cost.
[0108] The embodiments described above are part of the embodiments of the present application, rather than all of the embodiments. The detailed description of the embodiments of the present application is not intended to limit the scope of the present application for protection, but merely represents the selected embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present application.
Claims
1. A fluorescent immunoassay myocardial multiplex kit, characterized in that: It includes: A housing, a chromatography buffer, and a plurality of test cards disposed on the housing; At least three card slots are arranged in the housing, and the detection cards correspond to the card slots one by one; The detection card comprises a bottom plate and a blood filter pad, a gold spray pad, a detection pad and a water absorbent pad overlapped on the bottom plate; The gold-sprayed pad is sprayed with a fluorescent microsphere-antibody conjugate, and the detection pad is provided with a detection band and a quality control band, wherein the detection band is coated with a preset antibody; and the quality control band is coated with biotinylated-BSA; The antibodies are at least three of troponin I antibodies, myoglobin antibodies, creatine kinase isoenzyme antibodies, hypersensitivity, C-reactive protein antibodies, B-type natriuretic peptide antibodies and D-dimer antibodies.
2. The myocardial fluorescence immunoassay multiplex kit according to claim 1, characterized in that: The shell is provided with a sample adding area, and the sample adding area is communicated with the blood filter pad.
3. The myocardial fluorescence immunoassay multiplex kit according to claim 1, characterized in that: The shell is provided with a mixing tank.
4. The myocardial fluorescence immunoassay multiplex kit according to claim 1, characterized in that: The fluorescent microsphere-antibody coupling conjugate contains streptavidin.
5. The myocardial fluorescence immunoassay multiplex kit according to claim 1, characterized in that: The chromatography buffer comprises the following components: 0.1-0.2 mM phosphate buffer, 0.1-0.5% by volume of Tween-20, and 0.1-0.2% by volume of Proclin 300 preservative.
6. A method for preparing the fluorescent immunoassay multiple myocardial test kit according to any one of claims 1 to 5, characterized in that: The preparation steps are as follows: Activating the fluorescent microspheres, coupling a preset antibody on the surface of the microspheres after activation, modifying the microspheres with streptavidin to obtain a fluorescent microsphere-antibody conjugate, spraying the fluorescent microsphere-antibody conjugate on a glass fiber membrane, and drying for later use; Use nitrocellulose membrane as the detection pad chromatography test paper, coat the front end of the membrane strip with detection antibody as the detection band T line, and coat the back end of the membrane strip with biotinylated-BSA as the quality control band C line. After the antibody coating is drawn, it is dried and baked for use; The blood filter pad, the gold spray pad, the detection pad and the water absorbent pad are sequentially bonded to the bottom plate and laminated tightly, and then the laminated film strips are cut to obtain the detection card, and then the detection card is matched to the card slot on the housing; Finally, the prepared chromatography buffer and the assembled detection card are packed into a box to obtain a test kit.
7. The method for preparing the fluorescent immunoassay multiple myocardial test kit according to claim 6, characterized in that: The preservation solution comprises: phosphate buffer with a concentration of 0.1-1 mM, Tween-20 with a volume percentage of 0.01-4%, a preservative with a volume percentage of 0.05-0.1% and a protein with a mass percentage of 0.1-0.5%.
8. The method for preparing the fluorescent immunoassay multiple myocardial test kit according to claim 6, characterized in that: The spraying concentration of the fluorescent microsphere-antibody conjugate is 1.0-1.2 mg / mL.
9. The method for preparing the fluorescent immunoassay multiple myocardial test kit according to claim 6, characterized in that: The drying of the detection pad is specifically performed by air-drying at 20-30° C. for 1 hour, and the baking step is specifically performed by baking at 37° C. for 12 hours and then baking at 60° C. for 72 hours.
10. Use of the fluorescent immunoassay myocardial multiplex kit according to any one of claims 1 to 5 in the detection of cardiovascular index concentrations.
